Behçet hastalığında oküler bulgular ve tedavide yenilikler

Behçet Hastalığı, etyolojisi bilinmeyen, oral aftöz ülserler, genital ülserler, cilt lezyonları ve üveitin tekrarlayan atakları ile karakterize, vasküler, gastrointestinal, solunum ve santral sinir sistemini etkileyen sistemik inflamatuar bir hastalıktır. Behçet Hastalığının tedavisi semptomatik olmasına rağmen, son yıllarda, akut inflamatuar lezyonların erken ve etkili tedavisi ve nükslerin önlenmesi, hastalık sürecinin daha iyi olmasını sağlar. Antiinflamatuar ve/veya immunsupresif tedavi, hastalık ciddiyeti ve prognostik faktörlere göre ayarlanmalıdır. Azothioprin, siklosporin, interferon-α ve infliksimab gibi daha güçlü ilaçlar, Behcet Hastalığının daha ciddi sistemik bulgularını baskılamakta etkilidir. Bu derleme, Behçet hastalığının klinik özellikleri, tanısı, epidemiyoloji, etyoloji ve tedavisi ile ilgili genel bir bakış sağlamaktadır.

Ocular findings and new approaches in Behcet’s disease

Behcet’s disease, a systemic inflammatory disorder of unknown aetiology, is characterised by recurrent attacks of oral aphthous ulcers, genital ulcers, skin lesions, uveitis or other manifestations affecting gastrointestinal tract, and respiratory and central nervous systems. Although the treatment of Behcet’s disease is symptomatic, in recent years, it has been shown that early and effective treatment of acute inflammatory lesions and prevention of relapses can help to improve outcome. Anti-inflammatory and/or immunosuppressive treatments should be tailored according to the disease severity and prognostic factors. More potent drugs, such as azathioprine, cyclosporin, interferon-α and infliximab, are effective in the suppression of more severe systemic features of Behcet’s disease. This review provides an overview of the clinical feature, diagnosis, epidemiology, etiology and treatment of Behcet’s disease.

PDF

___

1. Evereklioğlu C.Current concepts in the etiology and treatment of Behçet Disease. Surv Ophthalmol 2005;50:297-349.
2. Gul A.Standart and novel therapeutic approaches to Behçet’s Disease. Drugs 2007;67(14):2013-2022.
3. Ando K, Fujino Y, Hijikata K, et al. Epidemiological features and visual prognosis of Behçet’s disease. Jpn J Ophthalmol 1999;43(4):312- 317.
4. Alpsoy E, Donmez L, Bacanli A, et al. Review of the chronologyof clinical manifestations in 60 patients with Behcet’s disease. Dermatology 2003;207:354–356.
5. de Smet MD, Bitar G, Mainigi S, Nussenblatt RB. Human S-antigen determinant recognition in uveitis. Invest Ophthalmol Vis Sci 2001;42;3233–3238.
6. Boyd SR, Young S, Lightman S: Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol 2001;46:209–233.
7. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992;62:60–65.
8. Bayazit YA, Everekliogˇlu C, Ozer E, et al. Neurotological status in Behcet’s disease and its ophthalmological correlates. Postgrad Med J 2004;80:724–728.
9. Coskun M, Bacanli A, Sallakci N, et al. Specific interleukin-1 gene polymorphisms in Turkish patients with Behcet’s disease. Exp Dermatol 2005; 14:124–129.
10. Evans CA, Jellis J, Hughes SP, et al. Tumor necrosis factor-alpha, interleukin-6, and interleukin-8 secretion and the acutephase response in patients with bacterial and tuberculous osteomyelitis. J Infect Dis 1998; 177:1582–1587.
11. Elgin U, Berker N, Batman A. Incidence of secondary glaucoma in Behcet disease. J Glaucoma 2004;13:441–444.
12. International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet 1990;335:1078–1080.
13. Caca I, Nazaroglu H,U nlu K, et al. Color doppler imaging of ocular hemodynamic changes in Behcet’s disease. Jpn J Ophthalmol 2004; 48:101–105.
14. BenEzra D, Cohen E. Treatment and visual prognosis in Behcet’s disease. Br J Ophthalmol 1986;70:589–592.
15. Goker B, Goker H. Current therapy for Behcet’s disease. Am J Ther 2002;9:465–470.
16. Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye 1998; 12:783–788.
17. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40:769–774.
18. Atmaca LS, Batioglu F. The efficacy of cyclosporin A in the treatment of Behcet’s disease. Ophthalmic Surg 1994; 25:321– 327.
19. Azizlerli G, Sarica R, Kose A, et al. Interferon alfa-2a in the treatment of Behcet’s disease. Dermatology 1996; 192:239–241.
20. Benitez-De-Castillo JM, Martinez-De-La-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti- TNFalpha (infliximab). Eye 2005;19(8):841-845.
21. Falappone PC, Iannone F, Scioscia C, et al. The treatment of recurrent uveitis with TNF-alpha inhibitors. Reumatismo 2004;56:185–189.
22. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449–1453.
23. Arayssi T, Hamra R, Awwad S, et al. Treatment of refractory vitritis in Behcet disease with infliximab. Arthritis Rheum 2002; 46:181.
24. Kanekura T, Gushi A, Iwata M, et al. Treatment of Behcet’s disease with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol 2004;51:83–87.
25. Kim CY, Kang SJ, Lee SJ, et al. Opacification of a hydrophilic acrylic intraocular lens with exacerbation of Behcet’s uveitis. J Cataract Refract Surg 2002;28:1276–1278.